| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Silver NanoParticles (AgNPs) Summary: 1.Smaller sizes are generally more bioactive due to increased surface area and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect. 2.Two relevant forms: particulate silver (AgNPs) and ionic silver (Ag⁺). There is debate regarding oral use, as Ag⁺ can precipitate as AgCl in gastric acid, reducing bioavailability; AgNPs may partially avoid this via particulate uptake and intracellular Ag⁺ release. Gastric pH may influence this equilibrium. 3. Dose example 80kg person: 1.12-2mg/day, which can be calculated based on ppm and volume taken (see below) target < 10ppm and 120mL per day (30ppm and 1L per day caused argyria 30mg/day ) (Case Report: 9‐15 ppm@120mL, i.e. 1.1mg/L to 1.8mg/L per day) Likely 10ppm --> 10mg/L, hence if take 100mL, then 1mg/day? (for Cancer) The current Rfd for oral silver exposure is 5 ug/kg/d with a critical dose estimated at 14 ug/kg/d for the average person. Seems like the Cancer target range is 14ug/kg/day to 25ug/kg/day. 80Kg example: 1.12mg to 2mg “1.4µg/kg body weight. If I would have 70kg, I would want to use 100µg/day. However, for fighting active disease, I would tend to explore higher daily dose, as I think this may be too low.” These values reflect experimental or anecdotal contexts and are not established safe or therapeutic doses. 4. Antioxidants such as NAC can counteract AgNP cytotoxicity by restoring glutathione pools and suppressing ROS-mediated mitochondrial damage. 5. In vitro studies commonly show ROS elevation in both cancer and normal cells; however, in vivo, superior antioxidant, NRF2, and repair capacity in normal tissues may confer selectivity. 6. Pathways/mechanisms of action/: -” intracellular ROS was increased...reduction in levels of glutathione (GSH)” - Normal-cell selectivity is partly mediated by NRF2-dependent antioxidant and detoxification responses. - AgNPs impair mitochondrial electron transport, increasing electron leak and amplifying ROS upstream of ΔΨm collapse. -AgNPs inhibit VEGF-driven endothelial signaling and permeability (anti-angiogenic effect) -”upregulation of proapoptotic genes (p53, p21, Bax, and caspases) and downregulation of antiapoptotic genes (Bcl-2)” -” upregulation of AMPK and downregulation of mTOR, MMP-9, BCL-2, and α-SMA” -”p53 is a key player...proapoptotic genes p53 and Bax were significantly increased... noticeable reduction in Bcl-2 transcript levels” -” p53 participates directly in the intrinsic apoptosis pathway by regulating the mitochondrial outer membrane permeabilization” - “Proapoptotic markers (BAX/BCL-XL, cleaved poly(ADP-ribose) polymerase, p53, p21, and caspases 3, 8 and 9) increased.” -”The antiapoptotic markers, AKT and NF-kB, decreased in AgNP-treated cells.” Chronic accumulation and long-term systemic effects remain insufficiently characterized. Silver NanoParticles and Magnetic Fields Summary: 1. “exposure to PMF increased the ability of AgNPs uptake” 2. 6x improvement from AgNPs alone could glucose capping of SilverNPs work as trojan horse? Sodium selenite might protect against toxicity of AgNPs in normal cells. -uncoated AgNPs can degrade the gut microbiome. PVP, citrate, green-synthesized, chitosan coating, may reduce the effect. Similar oxidative considerations may apply to selenium compounds, though mechanisms differ. co-ingestion with food (higher pH) favors reduction and lower Ag+ levels. -action mechanisms of AgNPs: the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure. AgNP anticancer effects come from three overlapping mechanisms: -Nanoparticle–cell interaction (uptake, membrane effects) -Intracellular ROS generation -Controlled Ag⁺ release inside cancer cells Comparison adding Citrate Capping | Property | Uncapped AgNPs | Citrate-capped AgNPs | | --------------------- | -------------- | -------------------- | | Stability | Poor | Excellent | | Free Ag⁺ | High | Low | | Normal cell toxicity | Higher | Lower | | Cancer selectivity | Lower | **Higher** | | Mechanism specificity | Crude | **Targeted** | | Storage behavior | Degrades | Stable |
|
| 4379- | AgNPs, | Exposure to silver nanoparticles induces size- and dose-dependent oxidative stress and cytotoxicity in human colon carcinoma cells |
| - | in-vitro, | CRC, | LoVo |
| 4380- | AgNPs, | Silver nanoparticles induce toxicity in A549 cells via ROS-dependent and ROS-independent pathways |
| - | in-vitro, | Lung, | A549 |
| 4381- | AgNPs, | Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells |
| - | in-vitro, | Liver, | HepG2 |
| 4382- | AgNPs, | Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism |
| - | in-vitro, | Nor, | RAW264.7 |
| 4383- | AgNPs, | Exploring the Potentials of Silver Nanoparticles in Overcoming Cisplatin Resistance in Lung Adenocarcinoma: Insights from Proteomic and Xenograft Mice Studies |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | A549 |
| 4385- | AgNPs, | Hepatoprotective effect of engineered silver nanoparticles coated bioactive compounds against diethylnitrosamine induced hepatocarcinogenesis in experimental mice |
| - | in-vitro, | Liver, | NA |
| 4386- | AgNPs, | Evaluation of hepatic cancer stem cells (CD73+, CD44+, and CD90+) induced by diethylnitrosamine in male rats and treatment with biologically synthesized silver nanoparticles |
| 4387- | AgNPs, | Attenuation of diethylnitrosamine (DEN) - Induced hepatic cancer in experimental model of Wistar rats by Carissa carandas embedded silver nanoparticles |
| - | in-vitro, | Liver, | NA |
| 4377- | AgNPs, | Interaction between silver nanoparticles of 20 nm (AgNP20 ) and human neutrophils: induction of apoptosis and inhibition of de novo protein synthesis by AgNP20 aggregates |
| - | in-vitro, | NA, | NA |
| 4389- | AgNPs, | Graphene Oxide-Silver Nanocomposite Enhances Cytotoxic and Apoptotic Potential of Salinomycin in Human Ovarian Cancer Stem Cells (OvCSCs): A Novel Approach for Cancer Therapy |
| - | in-vitro, | Ovarian, | NA |
| 4390- | AgNPs, | Therapeutic Potential of Cucumis melo (L.) Fruit Extract and Its Silver Nanopartciles Against DEN-Induced Hepatocellular Cancer in Rats |
| - | in-vivo, | Liver, | NA |
| 4391- | AgNPs, | Silver Nanoparticles Induce Apoptosis in HepG2 Cells through Particle-Specific Effects on Mitochondria |
| - | NA, | Liver, | HepG2 |
| 4392- | AgNPs, | Hepatocurative activity of biosynthesized silver nanoparticles fabricated using Andrographis paniculata |
| - | in-vivo, | LiverDam, | NA |
| 4393- | AgNPs, | Nanotoxic Effects of Silver Nanoparticles on Normal HEK-293 Cells in Comparison to Cancerous HeLa Cell Line |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 |
| 4394- | AgNPs, | Silver nanoparticles provoke apoptosis of Dalton's ascites lymphoma in vivo by mitochondria dependent and independent pathways |
| - | in-vivo, | lymphoma, | NA |
| 4395- | AgNPs, | Hepatoprotective effect of silver nanoparticles synthesized using aqueous leaf extract of Rhizophora apiculata |
| - | in-vivo, | LiverDam, | NA |
| - | in-vitro, | OS, | MG63 |
| 4368- | AgNPs, | Silver nanoparticles crossing through and distribution in the blood-brain barrier in vitro |
| - | NA, | Nor, | NA |
| 4359- | AgNPs, | Antimicrobial Silver Nanoparticles for Wound Healing Application: Progress and Future Trends |
| - | NA, | Wounds, | NA |
| 4360- | AgNPs, | Silver Nanoparticles as Real Topical Bullets for Wound Healing |
| - | Study, | Nor, | NA |
| 4361- | AgNPs, | GoldNP, | Biocompatible silver, gold and silver/gold alloy nanoparticles for enhanced cancer therapy: in vitro and in vivo perspectives |
| - | in-vivo, | Liver, | HepG2 |
| 4362- | AgNPs, | Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vivo, | NA, | NA |
| 4363- | AgNPs, | Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma |
| - | in-vivo, | fibroS, | NA |
| 4364- | AgNPs, | Selective cytotoxicity of green synthesized silver nanoparticles against the MCF-7 tumor cell line and their enhanced antioxidant and antimicrobial properties |
| - | in-vitro, | BC, | MCF-7 |
| 4365- | AgNPs, | Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview |
| - | Review, | Var, | NA |
| 4366- | AgNPs, | Gut Dysbiosis and Neurobehavioral Alterations in Rats Exposed to Silver Nanoparticles |
| - | in-vivo, | Nor, | NA |
| 4367- | AgNPs, | Effects of Prolonged Silver Nanoparticle Exposure on the Contextual Cognition and Behavior of Mammals |
| - | in-vivo, | Nor, | NA |
| 392- | AgNPs, | Biogenic silver nanoparticles synthesized from Piper longum fruit extract inhibit HIF-1α/VEGF mediated angiogenesis in prostate cancer cells |
| 4369- | AgNPs, | Silver nanoparticles induce p53-mediated apoptosis in human bronchial epithelial (BEAS-2B) cells |
| - | in-vitro, | Nor, | BEAS-2B |
| 4370- | AgNPs, | Effect of silver nanoparticles in the induction of apoptosis on human hepatocellular carcinoma (HepG2) cell line |
| - | in-vitro, | Liver, | HepG2 |
| 4371- | AgNPs, | Effects of Green Silver Nanoparticles on Apoptosis and Oxidative Stress in Normal and Cancerous Human Hepatic Cells in vitro |
| - | in-vitro, | Liver, | HUH7 |
| 4372- | AgNPs, | Negligible particle-specific toxicity mechanism of silver nanoparticles: the role of Ag+ ion release in the cytosol |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 4373- | AgNPs, | In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells |
| - | in-vitro, | Liver, | HepG2 |
| 4374- | AgNPs, | Enhancing antitumor activity of silver nanoparticles by modification with cell-penetrating peptides |
| - | in-vitro, | BC, | MCF-7 |
| 4375- | AgNPs, | The cellular uptake and cytotoxic effect of silver nanoparticles on chronic myeloid leukemia cells |
| - | in-vitro, | AML, | K562 |
| 4376- | AgNPs, | Interaction of multi-functional silver nanoparticles with living cells |
| - | in-vitro, | Nor, | L929 | - | in-vitro, | Lung, | A549 |
| 344- | AgNPs, | Cytotoxicity and ROS production of manufactured silver nanoparticles of different sizes in hepatoma and leukemia cells |
| - | in-vitro, | Liver, | HepG2 |
| 334- | AgNPs, | Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53 |
| - | in-vitro, | Colon, | HCT116 |
| 335- | AgNPs, | PDT, | Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy |
| - | Review, | NA, | NA |
| 336- | AgNPs, | PDT, | Photodynamic ability of silver nanoparticles in inducing cytotoxic effects in breast and lung cancer cell lines |
| - | in-vitro, | BC, | MCF-7 |
| 337- | AgNPs, | immuno, | Silver nanoparticle induced immunogenic cell death can improve immunotherapy |
| - | Review, | NA, | NA |
| 338- | AgNPs, | Biogenic silver nanoparticles: In vitro and in vivo antitumor activity in bladder cancer |
| - | vitro+vivo, | Bladder, | 5637 |
| 339- | AgNPs, | Cancer cell specific cytotoxic potential of the silver nanoparticles synthesized using the endophytic fungus, Penicillium citrinum CGJ-C2 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Melanoma, | A431 | - | in-vitro, | HCC, | HepG2 |
| 340- | AgNPs, | Screening bioactivities of Caesalpinia pulcherrima L. swartz and cytotoxicity of extract synthesized silver nanoparticles on HCT116 cell line |
| - | in-vitro, | CRC, | HCT116 |
| 341- | AgNPs, | Bioprospecting a native silver-resistant Bacillus safensis strain for green synthesis and subsequent antibacterial and anticancer activities of silver nanoparticles |
| - | in-vitro, | Liver, | HepG2 |
| 342- | AgNPs, | Silver nanoparticles; a new hope in cancer therapy? |
| - | Review, | NA, | NA |
| 343- | AgNPs, | Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma |
| - | in-vitro, | PC, | PANC1 |
| 333- | AgNPs, | HPT, | Enhancement effect of cytotoxicity response of silver nanoparticles combined with thermotherapy on C6 rat glioma cells |
| - | in-vivo, | GBM, | NA |
| 345- | AgNPs, | Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model |
| - | vitro+vivo, | lymphoma, | NA |
| 346- | AgNPs, | RSQ, | Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment |
| - | in-vivo, | Melanoma, | SK-MEL-28 | - | in-vivo, | Melanoma, | WM35 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:153 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid